- Home
- XAIR vs SXTP Comparison
XAIR vs SXTP Comparison
Compare XAIR & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XAIR | SXTP |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.5M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | XAIR | SXTP |
|---|---|---|
| Price | $0.43 | $1.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $10.00 | ★ $14.10 |
| AVG Volume (30 Days) | ★ 259.8K | 74.6K |
| Earning Date | 06-16-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,679,000.00 | N/A |
| Revenue This Year | $122.00 | $33.92 |
| Revenue Next Year | $58.15 | $51.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 107.26 | N/A |
| 52 Week Low | $0.33 | $0.34 |
| 52 Week High | $3.78 | $8.62 |
Technical Indicators
Market Signals| Indicator | XAIR | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 43.88 |
| Support Level | $0.43 | $1.29 |
| Resistance Level | $0.52 | $1.58 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 48.81 | 14.84 |
Price Performance
Historical ComparisonAbout XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.